These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1283581)

  • 1. Calcium overload--an important cellular mechanism in hypertension and arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Hofgärtner W; Fleckenstein A
    Drugs; 1992; 44 Suppl 1():23-30. PubMed ID: 1283581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental vasoprotection by calcium antagonists against calcium-mediated arteriosclerotic alterations.
    Fleckenstein-Grün G; Thimm F; Czirfuzs A; Matyas S; Frey M
    J Cardiovasc Pharmacol; 1994; 24 Suppl 2():S75-84. PubMed ID: 7898099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium--a neglected key factor in arteriosclerosis. The pathogenic role of arterial calcium overload and its prevention by calcium antagonists.
    Fleckenstein-Grün G; Fleckenstein A
    Ann Med; 1991; 23(5):589-99. PubMed ID: 1756029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differentiation between calcium- and cholesterol-dominated types of arteriosclerotic lesions: antiarteriosclerotic aspects of calcium antagonists.
    Fleckenstein-Grün G; Frey M; Thimm F; Luley C; Czirfusz A; Fleckenstein A
    J Cardiovasc Pharmacol; 1991; 18 Suppl 6():S1-9. PubMed ID: 1725909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists.
    Fleckenstein A; Frey M; Zorn J; Fleckenstein-Grün G
    Am J Cardiol; 1985 Dec; 56(16):3H-14H. PubMed ID: 2416214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of calcium in arteriosclerosis--experimental evaluation of antiarteriosclerotic potencies of Ca antagonists. Study Group for Calcium Antagonism.
    Fleckenstein-Grün G; Thimm F; Frey M; Czirfusz A
    Basic Res Cardiol; 1994; 89 Suppl 1():145-59. PubMed ID: 7945169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of calcium antagonists in heart and vascular smooth muscle.
    Fleckenstein A; Fleckenstein-Grün G
    Eur Heart J; 1988 Jun; 9 Suppl H():95-9. PubMed ID: 3049099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihypertensive and arterial anticalcinotic effects of calcium antagonists.
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Am J Cardiol; 1986 Feb; 57(7):1D-10D. PubMed ID: 3513510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium antagonists. Clinical use in the treatment of systemic hypertension.
    Spivack C; Ocken S; Frishman WH
    Drugs; 1983 Feb; 25(2):154-77. PubMed ID: 6339198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possibilities in the future application of calcium antagonists. Is the prevention of blood vessel calcinosis possible?].
    Fleckenstein A; Frey M; Fleckenstein-Grün G
    Fortschr Med; 1984 Jul; 102(27-28):713-7. PubMed ID: 6479813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium antagonism and ACE inhibition. Two outstandingly effective means of interference with cardiovascular calcium overload, high blood pressure, and arteriosclerosis in spontaneously hypertensive rats.
    Fleckenstein A; Fleckenstein-Grün G; Frey M; Zorn J
    Am J Hypertens; 1989 Mar; 2(3 Pt 1):194-204. PubMed ID: 2537646
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of calcium antagonists in progression of arteriosclerosis. Evidence from animal experiments and clinical experience. Part I. Preventive effects of calcium antagonists in animal experiments.
    Frey M; Just H
    Basic Res Cardiol; 1994; 89 Suppl 1():161-76. PubMed ID: 7945170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats.
    Vaja V; Ochodnicky P; Krenek P; Klimas J; Bajuszova Z; Kyselovic J
    Eur J Pharmacol; 2009 Oct; 619(1-3):85-91. PubMed ID: 19683522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of nifedipine on experimental arteriosclerosis.
    Knorr AM; Kazda S
    Cardiovasc Drugs Ther; 1990 Aug; 4 Suppl 5():1027-31. PubMed ID: 2076389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological basis for use of calcium antagonists in hypertension.
    Scriabine A; Kazda S
    Magnesium; 1989; 8(5-6):253-65. PubMed ID: 2693846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of various calcium antagonists against experimental arteriosclerosis.
    Fleckenstein-Grün G; Frey M; Thimm F; Fleckenstein A
    J Hum Hypertens; 1992 Dec; 6 Suppl 1():S13-8. PubMed ID: 1293304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
    Ishiguro K; Hayashi K; Sasamura H; Sakamaki Y; Itoh H
    Hypertension; 2009 Jan; 53(1):83-9. PubMed ID: 19047581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of calcium-channel antagonists in the heart of hypertensive and normotensive rats reveals class specific effects.
    Zwadlo C; Borlak J
    Vascul Pharmacol; 2016 Dec; 87():121-128. PubMed ID: 27613148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological basis for use of calcium channel antagonists in hypertension.
    Scriabine A; Kazda S; Garthoff B; Nickerson PA
    Angiology; 1988 Jan; 39(1 Pt 2):94-9. PubMed ID: 2449099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Future prospects for calcium antagonists.
    Kazda S
    Drugs; 1994; 48 Suppl 1():32-9. PubMed ID: 7533704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.